Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19659253 | 0.86 | EGLN2 (0.50) | NUDT1JAK1EGLN2PARP1TYK2 | |
| SCHEMBL19659252 | 0.80 | KDM4E (0.37) | NUDT1JAK1EGLN2TGFBR1PARP1 | |
| SCHEMBL2730240 | 0.79 | NUDT1 (0.62) | NUDT1JAK1PIM1EGLN2PARP1 | |
| SCHEMBL18366694 | 0.78 | NUDT1 (0.61) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL28485655 | 0.75 | AHR (0.47) | NUDT1PARP1 | |
| SCHEMBL22439076 | 0.75 | KDM4E (0.43) | NUDT1TGFBR1PARP1 | |
| SCHEMBL22888050 | 0.75 | EGLN2 (0.52) | NUDT1JAK1EGLN2JAK2JAK3 | |
| SCHEMBL18366704 | 0.75 | NUDT1 (0.38) | NUDT1JAK1EGLN2TYK2 | |
| SCHEMBL19659614 | 0.75 | KDM4E (0.43) | PARP1 | |
| SCHEMBL19658956 | 0.72 | PARP1 (0.39) | NUDT1JAK1PARP1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |